It's been a rough several months for TransMedics Group (NASDAQ: TMDX) shareholders. The stock has been beaten down by about ...

According to the lawsuit, throughout the Class Period, the Company and its senior executives misled investors and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, ...

New York, New York-- (Newsfile Corp. - March 13, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) ...

TransMedics Group (NASDAQ:TMDX – Get Free Report)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a ...

The organ transplant technology specialist significantly exceeded Wall Street's estimates in the fourth quarter.

TransMedics' strong Q4 performance and market share growth signal a promising future for investors. Click here to find out ...

SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- A class-action lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX), a medical technology company specializing in organ ...

TransMedics is revolutionizing organ transplant therapy with its FDA-approved Organ Care System. See why I rate TMDX stock as a buy.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

TransMedics Group (NasdaqGM:TMDX) saw its stock price rise by approximately 3% over the past month. This comes amidst the company's strong financial performance in the fourth quarter of 2024, with ...

It's been a rough several months for TransMedics Group (NASDAQ: TMDX) shareholders. The stock has been beaten down by about 62% from the peak it set last August. The company's warm perfusion ...

TransMedics Group's organ care system can preserve multiple organs, but livers are responsible for 70% of total sales. OrganOx markets a normothermic machine perfusion device approved to preserve ...